Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma in Relapse

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Study coordinator (Erick Herrscher, MBA) · erick.herrscher@mssm.edu · (212) 241-8615
Contact: Study coordinator (Nicole Devito, BSc) · nicole.devito@mountsinai.org · (212) 824-7367
Contact: Principal Investigator (Larysa Sanchez)

Study leads

Larysa Sanchez, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma · Myelodysplastic Syndromes (MDS) · Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States

Elranatamab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Myeloma · Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Boston, United States · Boston, United States

Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Xuzhou, China